HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, M. Articles by Slevin, J. T. Search for Related Content PubMed PubMed Citation Articles by Ryan, M. Articles by Slevin, J. T.

MELODY RYAN, PHARM.D., is Associate Professor, Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, and Department of Neurology, University of Kentucky College of Medicine (UKCM). JOHN T. SLEVIN, M.D., is Professor, Department of Neurology, UKCM, and Staff Neurologist, Department of Veterans Affairs Medical Center, Lexington.

Address correspondence to Dr. Ryan at the Department of Pharmacy Practice and Science, University of Kentucky, 725 Rose Street, Lexington, KY 40536-0082 (maryan1{at}email.uky.edu).

Purpose. The signs and symptoms, epidemiology, etiology, pathophysiology, diagnosis, pharmacologic and nonpharmacologic treatments, and options and guidelines for the treatment of restless legs syndrome (RLS) are reviewed. Summary. RLS was first described in the 17th century and further characterized in 1945. RLS is a common disorder, occurring in about 10% of the population. Patients with RLS often describe the urge to move, uncomfortable sensations, and pain, which begin or worsen during rest or inactivity such as lying or sitting. Symptoms of RLS make sleeping difficult for many patients, and significant daytime difficulties result from the condition. RLS can either be primary or arise from secondary causes that lead to iron deficiency. There is a familial component in primary RLS, but its underlying mechanisms remain unknown. Of individuals with conditions associated with iron-deficiency states, including pregnancy, renal failure, and anemia, 25–30% may develop RLS. The goals of RLS treatment include improving its symptoms and the patient’s quality of life. There are limited data on the treatment of RLS. Pharmacologic therapies include iron replacement, dopaminergic agents (e.g., levodopa), dopamine agonists, anticonvulsants, opioids, and benzodiazepines. There have been no systematic trials of nonpharmacologic therapies for RLS, but good sleep hygiene and avoidance of alcohol, caffeine, and nicotine may improve symptoms. Conclusion. RLS is a common disorder thought to involve abnormal iron metabolism and dopaminergic systems. Nonpharmacologic therapy should be suggested for all patients with RLS, but pharmacologic therapy may be required, and evidence is strongest for levodopa and dopamine agonists. Index terms: Alcohols, ethyl; Anticonvulsants; Antiparkinson agents; Benzodiazepines; Caffeine; Diagnosis; Dopamine agonists; Epidemiology; History; Iron preparations; Levodopa; Nicotine; Opiates; Protocols; Quality of life; Restless legs syndrome

 

This article has been cited by other articles:

				J. J Lee, J. Erdos, M. F Wilkosz, R. LaPlante, and B. Wagoner Bupropion as a Possible Treatment Option for Restless Legs Syndrome Ann. Pharmacother., February 1, 2009; 43(2): 370 - 374. [Abstract] [Full Text] [PDF]

				M. Ryan and J. T. Slevin Introduction: Treatment of Neurological Disorders Journal of Pharmacy Practice, April 1, 2007; 20(2): 115 - 116. [PDF]

				J. Suhl The Neuropharmacology of Sleep Disorders: Better Sleeping Through Chemistry? Journal of Pharmacy Practice, April 1, 2007; 20(2): 181 - 191. [Abstract] [PDF]